Literature DB >> 4734509

Primidone, diphenylhydantoin and phenobarbital. Aspects of acute and chronic toxicity.

B B Gallagher, I P Baumel, R H Mattson, S G Woodbury.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4734509     DOI: 10.1212/wnl.23.2.145

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  11 in total

Review 1.  Management of focal-onset seizures: an update on drug treatment.

Authors:  Svein I Johannessen; Elinor Ben-Menachem
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Ocular toxicity from systemic drug therapy. An overview of clinically important adverse reactions.

Authors:  S I Davidson; I G Rennie
Journal:  Med Toxicol       Date:  1986 May-Jun

Review 3.  Recent progress in epilepsy. Diagnostic procedures and treatment.

Authors:  B R Tharp
Journal:  Calif Med       Date:  1973-07

4.  Benign familial tremor treated with primidone.

Authors:  M Feely
Journal:  Br Med J (Clin Res Ed)       Date:  1981-02-28

5.  Double-blind controlled study of primidone in essential tremor.

Authors:  W R Gibb
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-16

6.  Neurological complications during medication of epilepsy patients.

Authors:  A I Boldyrev; E P Fleis
Journal:  Neurosci Behav Physiol       Date:  1982 Mar-Apr

7.  The effect of phenytoin and ethosuximide on primidone metabolism in patients with epilepsy.

Authors:  D Schmidt
Journal:  J Neurol       Date:  1975-06-09       Impact factor: 4.849

8.  The management of an epileptic disorder.

Authors:  M B Weber
Journal:  Can Fam Physician       Date:  1973-10       Impact factor: 3.275

Review 9.  Therapeutic drug monitoring of anticonvulsants. State of the art.

Authors:  I A Choonara; A Rane
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

Review 10.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.